Online citations, reference lists, and bibliographies.

Response Assessment In Pediatric Non-Hodgkin Lymphoma

T. Truong, V. Minard-Colin
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Response assessment is the clinical, biopathological, and radiological evaluation of disease at an interim time point during treatment or at the end of the therapy to determine and evaluate the success of therapy. Response determination during therapy for non-Hodgkin lymphoma is important because intensification of therapy for those with residual disease has been proven to be beneficial in some tumor types. Histological confirmation remains the gold standard to differentiate active residual disease from tumor necrosis or inflammatory scar tissue and allows for the application of highly sensitive techniques such as immunophenotyping by flow cytometry, cytogenetics and FISH analysis, and molecular PCR methods. Conventional cross-sectional imaging modalities such as CT are appealing for its ability to assess the entire tumor, is widely available and minimally invasive. Functional imaging with FDG-PET, though not available at all centers, has become an invaluable tool in staging and response assessment, but its role remains unclear and needs to be further evaluated in pediatric NHL. As pediatric NHL is well recognized to be a different spectrum of disease than adult NHL, the need for separate pediatric criteria led to a multidisciplinary collaboration resulting in the development of the International Pediatric NHL Response Criteria. Future use and adoption of these standardized criteria will allow for comparison of treatment efficacy across multiple regimens and improve clinical decision-making.
This paper references
International Pediatric Non-Hodgkin Lymphoma Response Criteria.
J. Sandlund (2015)
Revised response criteria for malignant lymphoma.
B. Cheson (2007)
Report on the First International Workshop on interim-PET scan in lymphoma
M. Meignan (2009)
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
A. Reiter (1995)
Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma.
C. Damm-Welk (2014)
Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B‐Cell Lymphoma treated with the AIEOP LNH‐97 protocol
M. Pillon (2016)
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
A. Reiter (1999)
The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
C. Patte (2001)
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.
M. Cairo (2007)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
M. Borowitz (2008)
Screening for Residual Disease in Pediatric Burkitt Lymphoma Using Consensus Primer Pools
M. Agsalda (2009)
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.
M. Roschewski (2015)
Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis
L. Mussolin (2013)
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
B. Cheson (1999)
The role of FDG‐PET/CT in the evaluation of residual disease in paediatric non‐Hodgkin lymphoma
D. Bhojwani (2015)
False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt's lymphoma
R. Riad (2010)
Pediatric Burkitt's Lymphoma and Diffuse B-Cell Lymphoma: Are Surveillance Scans Required?
Hassan M. Eissa (2014)
Distribution of NPM1‐ALK and X‐ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular–histological correlation
C. Damm-Welk (2009)
Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group.
E. Coustan-Smith (2009)
Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia.
M. Paganin (2014)
Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions.
A. Shammas (2009)
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
B. Cheson (2014)
Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead.
V. Minard-Colin (2015)
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.
C. Patte (2007)
Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children's Oncology Group
A. Termuhlen (2013)

Semantic Scholar Logo Some data provided by SemanticScholar